Learn More
Inflammation is associated with coronary artery disease (CAD), and statins reduce the inflammatory marker C-reactive protein (CRP). The effects of ezetimibe, alone or in combination with statins, on(More)
OBJECTIVE Patients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosis and cardiovascular disease (CVD). Despite extensive statin use, many patients with CVD(More)
Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. After stabilization on atorvastatin 10 mg, hypercholesterolemic subjects ≥65 years at high/very(More)
BACKGROUND Treatment response to lipid-lowering therapy can vary in patients with the metabolic syndrome (MetS) due to various patient demographic and baseline characteristics. OBJECTIVE This study(More)